Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06346600 · ClinicalTrials.gov registry record
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
A clinical trial of Neovascular (Wet) Age-Related Macular Degeneration, sponsored by Skyline Therapeutics.
- Recruiting
- Registry status
- 83
- Enrollment target
- 10
- Study locations
NCT06346600: Recruiting study of Neovascular (Wet) Age-Related Macular Degeneration, sponsored by Skyline Therapeutics.
NCT06346600 is a study of Neovascular (Wet) Age-Related Macular Degeneration that is actively recruiting participants, run by Skyline Therapeutics. The registered enrollment target is 83 participants. The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06346600, a study of Neovascular (Wet) Age-Related Macular Degeneration, is actively recruiting participants, sponsored by Skyline Therapeutics.
- RECRUITING
- Registry status
- 83 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.
Conditions Studied
Interventions
- GENETIC SKG0106
Study Locations (10)
Other
- Beijing Hospital - Beijing
- Peking Union Medical College Hospital - Beijing
- EYE & ENT Hospital of Fudan University - Shanghai
- Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine - Shanghai
Zhejiang
- Zhejiang Provincial People's Hospital - Hangzhou
- Eye Hospital, WMU (Zhejiang Eye Hospital) - Wenzhou
Massachusetts
- Ophthalmic Consultants of Boston - Boston
Texas
- Retina Consultants of Texas - Katy
Virginia
- Wagner Macula & Retina Center - Norfolk
Anhui
- The Second Hospital Of Anhui Medical University - Hefei
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2024-04-02 |
| Est. Completion | 2031-03 |
What NCT06346600 shows while recruiting
NCT06346600 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 83 participants, a relatively small participant target.
The record links to 1 condition, with Neovascular (Wet) Age-Related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which SKG0106 is the first listed.
NCT06346600 lists 10 locations in 6 states (Other, Zhejiang, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06346600 about?
NCT06346600 is a clinical study titled "A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD". This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and...
What is the current status of trial NCT06346600?
This trial is currently recruiting. The enrollment target is 83 participants. The study started on 2024-04-02. Estimated completion is 2031-03.
What conditions does trial NCT06346600 study?
This clinical trial studies the following conditions: Neovascular (Wet) Age-Related Macular Degeneration.
What interventions are being tested in trial NCT06346600?
The interventions under investigation include: SKG0106 (GENETIC).
Who is sponsoring clinical trial NCT06346600?
This trial is sponsored by Skyline Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06346600 being conducted?
This trial has 10 study locations across Massachusetts, Texas, Virginia, Anhui, Zhejiang. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular (Wet) Age-Related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI